Sentiment-Signal
14,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
16.1
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (26.03.2026)
HOCH Abgang Schlüsselpersonen (26.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 12.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 03.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 07.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 27.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 10.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 12.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 15.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Unternehmen & Branche
| Name | INCYTE CORP |
|---|---|
| Ticker | INCY |
| CIK | 0000879169 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 8731 · Services-Commercial Physical & Biological Research |
Wertpapier & Kennzahlen
| CUSIP | 45337c102 |
|---|---|
| ISIN | US45337C1027 |
| Typ | Common Stock |
| Marktkapitalisierung | 19,32 Mrd. USD |
| Beta | 0,86 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 5,141,242,000 | 1,286,650,000 | 6.41 | 6,957,973,000 | 5,167,478,000 |
| 2025-09-30 | 10-Q | 1,365,980,000 | 424,169,000 | 2.11 | 6,330,356,000 | 4,651,194,000 |
| 2025-06-30 | 10-Q | 1,215,529,000 | 404,999,000 | 2.04 | 5,821,354,000 | 4,170,903,000 |
| 2025-03-31 | 10-Q | 1,052,898,000 | 158,203,000 | 0.80 | 5,749,365,000 | 3,667,563,000 |
| 2024-12-31 | 10-K | 4,241,217,000 | 32,615,000 | 0.15 | 5,444,322,000 | 3,447,628,000 |
| 2024-09-30 | 10-Q | 1,137,871,000 | 106,456,000 | 0.54 | 5,012,434,000 | 3,171,220,000 |
| 2024-06-30 | 10-Q | 1,043,759,000 | -444,601,000 | -2.04 | 4,661,803,000 | 2,997,059,000 |
| 2024-03-31 | 10-Q | 880,889,000 | 169,548,000 | 0.75 | 7,135,605,000 | 5,394,271,000 |
| 2023-12-31 | 10-K | 3,695,649,000 | 597,599,000 | 2.65 | 6,782,107,000 | 5,189,837,000 |
| 2023-09-30 | 10-Q | 919,025,000 | 171,269,000 | 0.76 | 6,388,239,000 | 4,931,447,000 |
| 2023-06-30 | 10-Q | 954,610,000 | 203,548,000 | 0.90 | 6,208,259,000 | 4,740,692,000 |
| 2023-03-31 | 10-Q | 808,673,000 | 21,703,000 | 0.10 | 5,797,623,000 | 4,462,568,000 |
| 2022-12-31 | 10-K | 3,394,635,000 | 340,660,000 | 1.52 | 5,840,984,000 | 4,370,119,000 |
| 2022-09-30 | 10-Q | 823,303,000 | 112,775,000 | 0.50 | 5,510,214,000 | 4,226,651,000 |
| 2022-06-30 | 10-Q | 911,397,000 | 161,432,000 | 0.72 | 5,319,035,000 | 4,085,061,000 |
| 2022-03-31 | 10-Q | 733,235,000 | 37,992,000 | 0.17 | 5,054,221,000 | 3,863,072,000 |
| 2021-12-31 | 10-K | 2,986,267,000 | 948,581,000 | 4.27 | 4,933,352,000 | 3,770,004,000 |
| 2021-09-30 | 10-Q | 812,987,000 | 181,739,000 | 0.82 | 4,198,831,000 | 3,148,657,000 |
| 2021-06-30 | 10-Q | 705,709,000 | 149,456,000 | 0.67 | 3,904,623,000 | 2,935,861,000 |
| 2021-03-31 | 10-Q | 604,718,000 | 53,535,000 | 0.24 | 3,661,436,000 | 2,727,844,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 30,743,991 | 0 | 30,743,991 | 3,036,583,991 | Neu | +100,0% | |
| VANGUARD GROUP INC | 19,911,434 | 0 | 19,911,434 | 1,966,652,336 | Neu | +100,0% | |
| BlackRock, Inc. | 18,327,923 | 0 | 18,327,923 | 1,810,248,917 | Neu | +100,0% | |
| STATE STREET CORP | 9,656,403 | 0 | 9,656,403 | 953,762,924 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 6,720,024 | 0 | 6,720,024 | 663,736,788 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 4,993,012 | 0 | 4,993,012 | 491,499,628 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 3,978,332 | 0 | 3,978,332 | 392,939,852 | Neu | +100,0% | |
| Invesco Ltd. | 3,473,781 | 0 | 3,473,781 | 343,105,349 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3,094,460 | 0 | 3,094,460 | 305,639,814 | Neu | +100,0% | |
| MORGAN STANLEY | 2,663,823 | 0 | 2,663,823 | 263,105,935 | Neu | +100,0% | |
| Robeco Institutional Asset Management B.V. | 2,480,793 | 0 | 2,480,793 | 245,027,930 | Neu | +100,0% | |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2,284,317 | 0 | 2,284,317 | 225,621,990 | Neu | +100,0% | |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 2,288,874 | 0 | 2,288,874 | 211,926,843 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 1,788,190 | 0 | 1,788,190 | 176,620,167 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1,760,843 | 0 | 1,760,843 | 173,918,463 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,732,639 | 0 | 1,732,639 | 171,132,754 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,574,718 | 0 | 1,574,718 | 155,534,897 | Neu | +100,0% | |
| Legal & General Group Plc | 1,469,147 | 0 | 1,469,147 | 145,107,657 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 1,453,664 | 0 | 1,453,664 | 143,578,393 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 1,315,666 | 0 | 1,315,666 | 130,145,237 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 1,283,694 | 0 | 1,283,694 | 126,790,373 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 1,273,170 | 0 | 1,273,170 | 125,751,002 | Neu | +100,0% | |
| FMR LLC | 1,246,439 | 0 | 1,246,439 | 123,110,811 | Neu | +100,0% | |
| NORGES BANK | 1,244,233 | 0 | 1,244,233 | 122,892,893 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 1,116,382 | 0 | 1,116,382 | 110,265,000 | Neu | +100,0% | |
| Man Group plc | 1,099,329 | 0 | 1,099,329 | 108,580,725 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 1,072,491 | 0 | 1,072,491 | 105,929,937 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 1,003,440 | 0 | 1,003,440 | 99,109,792 | Neu | +100,0% | |
| PANAGORA ASSET MANAGEMENT INC | 992,115 | 0 | 992,115 | 97,991,199 | Neu | +100,0% | |
| SOUND SHORE MANAGEMENT INC /CT/ | 929,832 | 0 | 929,832 | 91,839,507 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 865,150 | 0 | 865,150 | 85,454,074 | Neu | +100,0% | |
| CITIGROUP INC | 852,328 | 0 | 852,328 | 84,184,437 | Neu | +100,0% | |
| VIRGINIA RETIREMENT SYSTEMS ET Al | 768,325 | 0 | 768,325 | 75,887,460 | Neu | +100,0% | |
| Skandinaviska Enskilda Banken AB (publ) | 754,116 | 0 | 754,116 | 74,499,120 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 739,378 | 0 | 739,378 | 73,028,364 | Neu | +100,0% | |
| RHUMBLINE ADVISERS | 684,283 | 0 | 684,283 | 67,586,526 | Neu | +100,0% | |
| UBS Group AG | 682,315 | 0 | 682,315 | 67,392,253 | Neu | +100,0% | |
| SEI INVESTMENTS CO | 663,446 | 0 | 663,446 | 65,529,229 | Neu | +100,0% | |
| AustralianSuper Pty Ltd | 640,733 | 0 | 640,733 | 63,285,198 | Neu | +100,0% | |
| CANADA PENSION PLAN INVESTMENT BOARD | 638,694 | 0 | 638,694 | 63,083,806 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 550,096 | 0 | 550,096 | 54,332,981 | Neu | +100,0% | |
| WORLDQUANT MILLENNIUM ADVISORS LLC | 531,693 | 0 | 531,693 | 52,515,318 | Neu | +100,0% | |
| IEQ CAPITAL, LLC | 525,172 | 0 | 525,172 | 51,871,279 | Neu | +100,0% | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 480,181 | 0 | 480,181 | 47,427,477 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 473,383 | 0 | 473,383 | 46,756,039 | Neu | +100,0% | |
| Candriam S.C.A. | 460,070 | 0 | 460,070 | 45,443,048 | Neu | +100,0% | |
| Swiss National Bank | 454,874 | 0 | 454,874 | 44,927,905 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 443,436 | 0 | 443,436 | 43,798,175 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 438,125 | 0 | 438,125 | 43,273,606 | Neu | +100,0% | |
| MACKENZIE FINANCIAL CORP | 410,362 | 0 | 410,362 | 40,509,053 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | CAGNONI PABLO J | Officer, President, Global Head of R&D | Open Market Sale | -18,667 | 96.50 | -1,801,365.50 | -185,0% | |
| 2026-03-17 | CAGNONI PABLO J | Officer, President, R&D | Open Market Sale | -18,667 | 94.24 | -1,759,178.08 | -180,6% | |
| 2026-02-19 | CAGNONI PABLO J | Officer, President, R&D | Open Market Sale | -18,668 | 100.91 | -1,883,787.88 | -193,4% | |
| 2026-01-07 | Issa Mohamed Khairie | Officer, EVP, Head of US Oncology | Open Market Sale | -10,856 | 109.07 | -1,184,063.92 | -121,6% | |
| 2026-01-05 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -15,634 | 101.70 | -1,589,977.80 | -163,3% | |
| 2025-12-19 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -2,774 | 100.00 | -277,400.00 | -28,5% | |
| 2025-12-18 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -600 | 98.25 | -58,950.00 | -6,1% | |
| 2025-12-17 | Morrissey Michael James | Officer, EVP, Head of Tech. Operations | Open Market Sale | -4,323 | 97.26 | -420,454.98 | -43,2% | |
| 2025-12-16 | Morrissey Michael James | Officer, EVP, Head of Tech. Operations | Open Market Sale | -833 | 97.42 | -81,150.86 | -8,3% | |
| 2025-12-16 | Morrissey Michael James | Officer, EVP, Head of Tech. Operations | Open Market Sale | -53,175 | 97.29 | -5,173,395.75 | -531,2% | |
| 2025-12-11 | Mayes Patrick A | Officer, EVP & Chief Scientific Officer | Open Market Sale | -255 | 94.94 | -24,209.70 | -2,5% | |
| 2025-12-10 | Mayes Patrick A | Officer, EVP & Chief Scientific Officer | Open Market Sale | -5,553 | 95.58 | -530,755.74 | -54,5% | |
| 2025-12-02 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -20,105 | 102.51 | -2,060,963.55 | -211,6% | |
| 2025-12-01 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -2,559 | 102.96 | -263,474.64 | -27,1% | |
| 2025-11-24 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -600 | 103.00 | -61,800.00 | -6,3% | |
| 2025-11-21 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -169 | 102.00 | -17,238.00 | -1,8% | |
| 2025-11-17 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -278 | 104.36 | -29,012.08 | -3,0% | |
| 2025-11-10 | Hoppenot Herve | Director | Open Market Sale | -187,500 | 105.46 | -19,773,750.00 | -2030,3% | |
| 2025-11-05 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -5,233 | 102.20 | -534,812.60 | -54,9% | |
| 2025-11-04 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -598 | 101.36 | -60,613.28 | -6,2% | |
| 2025-11-03 | Heeson Lee | Officer, EVP, Head of Incyte Intl | Open Market Sale | -3,074 | 94.02 | -289,017.48 | -29,7% | |
| 2025-10-15 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -277 | 85.13 | -23,581.01 | -2,4% | |
| 2025-10-03 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -3,501 | 85.54 | -299,475.54 | -30,7% | |
| 2025-10-02 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -599 | 87.65 | -52,502.35 | -5,4% | |
| 2025-09-16 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -278 | 83.15 | -23,115.70 | -2,4% | |
| 2025-09-02 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -598 | 84.97 | -50,812.06 | -5,2% | |
| 2025-08-15 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -277 | 86.81 | -24,046.37 | -2,5% | |
| 2025-08-04 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -598 | 75.77 | -45,310.46 | -4,7% | |
| 2025-07-21 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -3,706 | 67.94 | -251,785.64 | -25,9% | |
| 2025-07-16 | Iyengar Vijay K | Officer, EVP, GMAPPS | Open Market Sale | -983 | 68.36 | -67,197.88 | -6,9% | |
| 2025-07-16 | Flannelly Barry P | Officer, EVP & General Manager US | Open Market Sale | -1,340 | 68.36 | -91,602.40 | -9,4% | |
| 2025-07-16 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -785 | 68.36 | -53,662.60 | -5,5% | |
| 2025-07-15 | Iyengar Vijay K | Officer, EVP, GMAPPS | Open Market Sale | -1,177 | 69.86 | -82,225.22 | -8,4% | |
| 2025-07-15 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -3,330 | 69.86 | -232,633.80 | -23,9% | |
| 2025-07-15 | Flannelly Barry P | Officer, EVP & General Manager US | Open Market Sale | -1,192 | 69.86 | -83,273.12 | -8,6% | |
| 2025-07-14 | Stein Steven H | Officer, EVP & Chief Medical Officer | Open Market Sale | -14,952 | 68.47 | -1,023,763.44 | -105,1% | |
| 2025-07-03 | Iyengar Vijay K | Officer, EVP, GMAPPS | Open Market Sale | -2,682 | 68.16 | -182,805.12 | -18,8% | |
| 2025-07-03 | Flannelly Barry P | Officer, EVP & General Manager US | Open Market Sale | -10,903 | 68.15 | -743,039.45 | -76,3% | |
| 2025-07-03 | Iyengar Vijay K | Officer, EVP, GMAPPS | Open Market Sale | -5,935 | 68.15 | -404,470.25 | -41,5% | |
| 2025-07-02 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -599 | 68.61 | -41,097.39 | -4,2% | |
| 2025-06-03 | Denton Sheila A. | Officer, EVP & General Counsel | Open Market Sale | -1,795 | 68.00 | -122,060.00 | -12,5% | |
| 2025-06-02 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -651 | 64.88 | -42,236.88 | -4,3% | |
| 2025-05-30 | Tray Thomas | Officer, Principal Accounting Officer | Open Market Sale | -963 | 65.71 | -63,278.73 | -6,5% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| BAKER BROS. ADVISORS LP | 30,743,991 | 3,036,583,991 | 19.19 |
| VANGUARD GROUP INC | 19,911,434 | 1,966,652,336 | 12.43 |
| BlackRock, Inc. | 18,327,923 | 1,810,248,917 | 11.44 |
| STATE STREET CORP | 9,656,403 | 953,762,924 | 6.03 |
| AQR CAPITAL MANAGEMENT LLC | 6,720,024 | 663,736,788 | 4.19 |
| GEODE CAPITAL MANAGEMENT, LLC | 4,993,012 | 491,499,628 | 3.11 |
| RENAISSANCE TECHNOLOGIES LLC | 3,978,332 | 392,939,852 | 2.48 |
| Invesco Ltd. | 3,473,781 | 343,105,349 | 2.17 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3,094,460 | 305,639,814 | 1.93 |
| MORGAN STANLEY | 2,663,823 | 263,105,935 | 1.66 |
| Robeco Institutional Asset Management B.V. | 2,480,793 | 245,027,930 | 1.55 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2,284,317 | 225,621,990 | 1.43 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 2,288,874 | 211,926,843 | 1.34 |
| DIMENSIONAL FUND ADVISORS LP | 1,788,190 | 176,620,167 | 1.12 |
| NORTHERN TRUST CORP | 1,760,843 | 173,918,463 | 1.10 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,732,639 | 171,132,754 | 1.08 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,574,718 | 155,534,897 | 0.98 |
| Legal & General Group Plc | 1,469,147 | 145,107,657 | 0.92 |
| VICTORY CAPITAL MANAGEMENT INC | 1,453,664 | 143,578,393 | 0.91 |
| Pictet Asset Management Holding SA | 1,315,666 | 130,145,237 | 0.82 |